

Express Mail Label No.: EV922217542US
Date of Deposit: February 22, 2008



2-25-08

FFW

Attorney Docket No. 20363-013 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Kaelin et al.

SERIAL NUMBER: 10/533,839

EXAMINER: Hill, Kevin Kai

FILING DATE: March 14, 2006

ART UNIT: 1633

FOR: IN VIVO IMAGING OF E2F-REGULATED BIOLUMINESCENT
PROTEINS

MAIL STOP MISSING PARTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Response to Notice to Comply (1 page);
2. Copy of Notice to Comply (2 pages);
3. Sequence Listing: Paper Copy (2 pages);
4. Statement in Support of Computer Readable Form Submission (1 page);
5. Preliminary Amendment (4 pages);
6. Computer Readable Form Submission (1 disk); and
7. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 20363-013NATL. A duplicate copy of this transmittal letter is enclosed herewith.

 DISK TO STIC DATE : _____ 	No. 42,764
--	------------

Date of Deposit: February 22, 2008

Application No.
10/533,839Applicant(s)
Kaelin et al

Notice to Comply

Examiner
Kevin K. Hill, Ph.D.Art Unit
1633PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY
Detailed Action

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant has not filed a "Sequence Listing" for the SEQ ID numbers disclosed on page 12, lines 24-28, page 13, lines 8-13, and recited in the claims, thus precluding the Examiner from performing a search of the claimed invention.

Applicant is given **ONE (1) MONTH, or THIRTY (30) DAYS**, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in **ABANDONMENT** of the application under 37 CFR 1.821(g). Since this application has been granted special status under the accelerated examination program, **NO** extensions of time under 37 CFR 1.136(a) will be permitted.

Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.



The objective of the accelerated examination program is to complete the examination of an application within twelve months from the filing date of the application. Any reply must be filed electronically via EFS-Web so that the papers will be expeditiously processed and considered. If the reply is not filed electronically via EFS-Web, the final disposition of the application may occur later than twelve months from the filing of the application.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin K. Hill, Ph.D. whose telephone number is 571-272-8036. The examiner can normally be reached on Monday through Friday, between 9:00am-6:00pm EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave T. Nguyen can be reached on 571-272-0731. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 1 of 2

Q. JANICE LI, M.D.
PRIMARY EXAMINER



Notice to Comply

Application No.
10/533,839

Applicant(s)
Kaelin et al

Examiner
Kevin K. Hill, Ph.D.

Art Unit
1633

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The sequences set forth in the specification and drawings lack sequence identifiers, specifically: page 12, lines 24-28 and page 13, lines 8-13.

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", **as well as an amendment specifically directing its entry into the application.**
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212 or 308-2923

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

Part of Paper No.

Page 2 of 2

Express Mail Label No.: EV922217542US
Date of Deposit: February 22, 2008



Attorney Docket No. 20363-013 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Kaelin et al.
SERIAL NUMBER: 10/533,839 EXAMINER: Hill, Kevin Kai
FILING DATE: March 14, 2006 ART UNIT: 1633
FOR: IN VIVO IMAGING OF E2F-REGULATED BIOLUMINESCENT PROTEINS


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (the "Notice") mailed January 24, 2008, Applicant submits herein a substitute computer readable form (CRF) copy of the "Sequence Listing", a substitute paper copy of the "Sequence Listing", a Statement in Support of Computer Readable Form Submission, a Preliminary Amendment, and a copy of the Notice. This response is due on or before February 24, 2008.

Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below. The Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 20363-013NATL.

Respectfully submitted,



Ivor R. Felfi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MNTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: February 22, 2008